← SynDRA
RAVOXERTINIB
SynDRA canonical compound SYN0038180 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | MAPK1 | MAPK3 |
|---|
| Mechanism of action | MAP kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- MAPK3 INHIBITOR
- MAP kinase ERK1 inhibitor
- MAPK1 INHIBITOR
- MAP kinase ERK2 inhibitor
- MEK inhibitor
- ERK1 and ERK2 phosphorylation inhibitor
Drug classes
- Antineoplastic Agents
- Protein Kinase Inhibitors
Cross-references
Synonyms
- GDC-0994
- GDC0994
- RG-7842
- R6AXV96CRH
- ravoxertinibum
- RefChem:930572
- ERK Inhibitor GDC-0994
- MFCD28143918
- Ravoxertinib [INN]
- Ravoxertinib [USAN]
- C21H18ClFN6O2
- 6QB
- UNII-R6AXV96CRH
- Ravoxertinib (USAN/INN)
- Ravoxertinib [USAN:INN]
- Ravoxertinib(GDC0994)?
- Ravoxertinib (GDC-0994)
- RAVOXERTINIB [WHO-DD]
- GTPL9229
- orb1300705
- SCHEMBL15245531
- SCHEMBL29358425
- RZUOCXOYPYGSKL-GOSISDBHSA-N
- BDBM120095
- EX-A1614
- NSC781343
- NSC800104
- RG7842
- AKOS027252126
- CCG-269131
- CS-3704
- EBC-224071
- NSC-781343
- NSC-800104
- example 39 [WO2013130976]
- NCGC00386401-02
- NCGC00386401-05
- AC-33149
- AS-55994
Look up RAVOXERTINIB in the interactive SynDRA portal →